Modality
Gene Editing
MOA
TYK2i
Target
SOS1
Pathway
Neuroinflam
IgAN
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
May 2023
→ Apr 2030
Phase 2Current
NCT06821382
2,337 pts·IgAN
2023-05→2030-04·Terminated
2,337 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-254.1y awayPh3 Readout· IgAN
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2030-04-25 · 4.1y away
IgAN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06821382 | Phase 2/3 | IgAN | Terminated | 2337 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |